search
Back to results

Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial (iPocc)

Primary Purpose

Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma

Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Paclitaxel(intravenous) + Carboplatin(intravenous)
Paclitaxel(intravenous) + Carboplatin(intraperitoneal)
Sponsored by
Gynecologic Oncology Trial & Investigation Consortium
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Epithelial Ovarian Cancer focused on measuring Epithelial ovarian cancer, Fallopian tube cancer, peritoneal cancer, intraperitoneal therapy, Carboplatin, Paclitaxel

Eligibility Criteria

20 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patients assumed to have a stageII-IV epithelial ovarian, fallopian tube, or primary peritoneal cancer as a pre-surgery diagnosis

  2. Patients scheduled to undergo laparotomy

    *Both optimal and suboptimal patients will be eligible for the study (Suboptimal patients, as well as those who undergo only exploratory laparotomy, are eligible.)

  3. ECOG Performance Status: 0-2
  4. Patients who provide consent for placement of the IP port system, if randomized to Regimen II (Study treatment: dd-TCip therapy)
  5. Patients expected to receive the first protocol treatment within 8 weeks after the comprehensive staging surgery

  6. Lab data and clinical examination: Data within 28 days before the scheduled date of surgery

    • Neutrophil count ≧ 1,500 /mm3
    • Platelet count ≧ 100,000 /mm3
    • AST (GOT) ≦ 100 IU/L
    • ALT (GPT) ≦ 100 IU/L
    • Total bilirubin < 1.5 mg/dL
    • Serum Creatinine < 1.5 mg/dL
    • Electrocardiogram (ECG): Patients with normal ECG, Asymptomatic patients with abnormal ECGs not requiring medical intervention
    • Neuropathy(Both motor and sensory) ≦ Grade1 (CTCAE Version 4.0)
  7. Patients expected to survive longer than 3 months from the start date of the protocol treatment
  8. Patients aged 20 years and older at the time of tentative registration (with no upper age limit)
  9. Patients who provide written informed consent for participation in this trial

Exclusion Criteria:

  1. Patients assumed to have a borderline malignancy of the ovary, fallopian tube, or primary peritoneal cancer
  2. Patients who have received previous chemotherapy or radiation therapy to treat the current disease
  3. Patients who have a synchronous malignancy or who have been progression-free less than 5 years for a metachronous malignancy (Patients with basal and squamous cell carcinoma of the skin, as well as carcinoma in situ, and intramucosal carcinoma cured by local treatment, are eligible for the study)
  4. Patients with serious medical complications, such as serious heart disease, cerebrovascular accidents, uncontrolled diabetes mellitus, uncontrolled hypertension, pulmonary fibrosis, interstitial pneumonitis, active bleeding, an active gastrointestinal ulcer, or a serious neurological disorder
  5. Patients who have had a hypersensitivity reaction to polyoxyethylated or hydrogenated castor oil
  6. Patients with a pleural effusion requiring continuous drainage
  7. Patients with an active infection requiring antibiotics
  8. Patients who are pregnant, nursing or of child-bearing potential
  9. Patients with evidence upon physical examination of brain tumor and any brain metastases
  10. Patients for whom completion of this study and/or follow-up is deemed inappropriate for any reason
  11. Patients with any signs/symptoms of interstitial pneumonia

Sites / Locations

  • University of Pittsburgh
  • Queen Mary Hospital
  • Aichi Cancer Center Hospital
  • Hirosaki University School of Medicine & Hospital
  • The Jikei University School of Medicine, Kashiwa Hospital
  • NHO Shikoku Cancer Center
  • Ehime University Hospital
  • University of Fukui Hospital
  • Gunma University Hospital
  • Gunma Prefectural Cancer Center
  • NHO Kure Medical Center And Chugoku Cancer Center
  • Miyoshi Central Hospital
  • Hyogo Cancer Center
  • Japanese Red Cross Society Himeji Hospital
  • Kobe City Medical Center General Hospital
  • Hyogo Medical College Hospital
  • Tsukuba University Hospital
  • Iwate Medical University Hospital
  • Tokai University Hospital
  • Nippon Medical University Musasi Kosugi Hospital
  • Yokohama Municipal Citizen's Hospital
  • Mie University Hospital
  • Mie Prefectural General Medical Center
  • Tohoku University Hospital
  • Shinshu University Hospital
  • Nara Medical Univeｒsity Hospital
  • Okinawa Prefectural Chubu Hospital
  • Kaizuka City Hospital
  • Osaka University Hospital
  • Osaka Medical College Hospital
  • Saitama Medical University International Medical Center
  • Saitama Medical University Saitama Medical Center
  • Shizuoka Cancer Center
  • Jichi Medical University Hospital
  • Tochigi Cancer Center
  • Juntendo University Hospital
  • The University of Tokyo Hospital
  • The Jikei University Daisan Hospital
  • The Cancer Institute Hospital Of JFCR
  • The Jikei University Hospital
  • Showa University Hospital
  • Keio University Hospital
  • Tokyo Women's Medical University Medical Center East
  • Tottori University
  • Yamaguchi University Hospital
  • NHO Kyusyu Medical center
  • JA Hiroshima General Hospital
  • Kagoshima City Hospital
  • University Hospital, Kyoto Prefectural University of Medicine
  • Saiseikai Nagasaki Hospital
  • Niigata Cancer Center Hospital
  • Niigata University Medical & Dental Hospital
  • Osaka Medical Center for Cancer and Cardiovascular Diseases
  • Tottori Municipal Hospital
  • Korea Cancer Center Hospital
  • Gangnam Severance Hospital in Korea
  • Asan Medical Center
  • Ewha Womans University Medical Center
  • Shinchon Severance Hospital
  • University of Otago - Christchurch/Christchurch Women's Hospital
  • KK Women's and Children's Hospital
  • National University Hospital of Singapore

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Standard treatment: dd-TCiv therapy

Study treatment: dd-TCip therapy

Arm Description

Paclitaxel administered by IV infusion weekly plus concurrent carboplatin administered by IV infusion once every 3 weeks

Paclitaxel administered by IV infusion weekly plus concurrent carboplatin administered by IP injection once every 3 weeks

Outcomes

Primary Outcome Measures

Progression-free survival(PFS)

Secondary Outcome Measures

Overall survival (OS)
Tumor response (only patients with evaluable disease)
Adverse events
Treatment completion rate
Quality of Life (QOL) assessments
Cost-utility analysis

Full Information

First Posted
December 20, 2011
Last Updated
September 13, 2023
Sponsor
Gynecologic Oncology Trial & Investigation Consortium
Collaborators
Japanese Gynecologic Oncology Group
search

1. Study Identification

Unique Protocol Identification Number
NCT01506856
Brief Title
Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial
Acronym
iPocc
Official Title
A Randomized Phase II/III Trial of Intravenous (IV) Paclitaxel Weekly Plus IV Carboplatin Once Every 3 Weeks Versus IV Paclitaxel Weekly Plus Intraperitoneal (IP) Carboplatin Once Every 3 Weeks in Women With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
September 2022
Overall Recruitment Status
Completed
Study Start Date
May 2010 (undefined)
Primary Completion Date
February 28, 2021 (Actual)
Study Completion Date
February 28, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Gynecologic Oncology Trial & Investigation Consortium
Collaborators
Japanese Gynecologic Oncology Group

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is: Phase A: To confirm the feasibility of paclitaxel administered by intravenous (IV) infusion weekly plus concurrent carboplatin administered by intraperitoneal (IP) injection once every 3 weeks (dd-TCip therapy). Phase B: To compare the efficacy and safety of the following two treatment regimens as first-line chemotherapy in women with epithelial ovarian, Fallopian tube or primary peritoneal cancer.
Detailed Description
This is a randomized, multicenter international study. Patient are stratified according to Residual tumor diameter([0cm(No residual)] vs. [0cm<residual<1cm] vs. [1cm<residual<2cm] vs. [>2 cm]), FIGO stage(StageII vs. III vs. IV) and institution. Patient randomized to one of the treatment arms described below. RegimenI(Standard treatment: dd-TCiv therapy): Paclitaxel administered by IV infusion weekly plus concurrent carboplatin administered by IV infusion once every 3 weeks RegimenII(Study treatment: dd-TCip therapy): Paclitaxel administered by IV infusion weekly plus concurrent carboplatin administered by IP injection once every 3 weeks The 3-week period (21 days) is 1 cycle. Protocol treatment basically comprises 6 cycles. IDS is allowed to be performed after 3, 4 or 5 cycles of the protocol treatment. In such cases, the protocol treatment must be restarted within 8 weeks after IDS. If IDS is performed, patients can receive up to 3 additional cycles of the protocol treatment after IDS. If interval debulking surgery (IDS) is performed after 3, 4 or 5 cycles, the patients can receive up to 3 additional cycles of the protocol treatment. A total of 6 to 8 cycles will be repeated. The analysis of efficacy will be performed on all randomized subjects in accordance with the intention-to-treat (ITT) principle. In order to assess the robustness of the results, the same analyses will be done using all randomized subjects who satisfy the eligibility criteria. The analysis of safety will be performed on all subjects who have received at least one dose of study treatment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Keywords
Epithelial ovarian cancer, Fallopian tube cancer, peritoneal cancer, intraperitoneal therapy, Carboplatin, Paclitaxel

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
655 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Standard treatment: dd-TCiv therapy
Arm Type
Active Comparator
Arm Description
Paclitaxel administered by IV infusion weekly plus concurrent carboplatin administered by IV infusion once every 3 weeks
Arm Title
Study treatment: dd-TCip therapy
Arm Type
Experimental
Arm Description
Paclitaxel administered by IV infusion weekly plus concurrent carboplatin administered by IP injection once every 3 weeks
Intervention Type
Drug
Intervention Name(s)
Paclitaxel(intravenous) + Carboplatin(intravenous)
Other Intervention Name(s)
Paclitaxel(Sawai),(NK), Paraplatin(BMS), Carboplatin(SANDOZ)
Intervention Description
Paclitaxel(intravenous) + Carboplatin(intravenous) Paclitaxel : 80mg/m2, IV infusion, Day1, 8, and 15 Carboplatin: AUC=6.0, IV infusion, Day1 A total of 6 to 8 cycles will be repeated.
Intervention Type
Drug
Intervention Name(s)
Paclitaxel(intravenous) + Carboplatin(intraperitoneal)
Other Intervention Name(s)
Paclitaxel(Sawai),(NK), Paraplatin(BMS), Carboplatin(SANDOZ)
Intervention Description
Paclitaxel(intravenous) + Carboplatin(intraperitoneal) Paclitaxel : 80mg/m2, IV infusion, Day1, 8, and 15 Carboplatin: AUC=6.0, IP injection, Day1 A total of 6 to 8 cycles will be repeated.
Primary Outcome Measure Information:
Title
Progression-free survival(PFS)
Time Frame
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed until 510 events are observed or until 3 years from the last patient is randomized to the study
Secondary Outcome Measure Information:
Title
Overall survival (OS)
Time Frame
weekly during the protocl treatment, then every 3 months for the first 2 years, 6-month for the following 2 years, and once a year thereafter
Title
Tumor response (only patients with evaluable disease)
Time Frame
every 2 cycles [after 2 cycles, after 4 cycles, after 6 cycles, (after 8 cycles)], the time of discontinuation of the protocol treatment and then at least annually during follow-up
Title
Adverse events
Time Frame
weekly during the protocl treatment, then every 3 months for the first 2 years, 6-month for the following 2 years, and once a year thereafter
Title
Treatment completion rate
Time Frame
After the last cycle of the protocol teatment
Title
Quality of Life (QOL) assessments
Time Frame
baseline, after 3 cycles, 6 cycles, 36 week, 60 weeks and 84 weeks from the start of protocol treatment
Title
Cost-utility analysis
Time Frame
baseline, after 3 cycles, 6 cycles, 36 week, 60 weeks and 84 weeks from the start of protocol treatment

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients assumed to have a stageII-IV epithelial ovarian, fallopian tube, or primary peritoneal cancer as a pre-surgery diagnosis Patients scheduled to undergo laparotomy *Both optimal and suboptimal patients will be eligible for the study (Suboptimal patients, as well as those who undergo only exploratory laparotomy, are eligible.) ECOG Performance Status: 0-2 Patients who provide consent for placement of the IP port system, if randomized to Regimen II (Study treatment: dd-TCip therapy) Patients expected to receive the first protocol treatment within 8 weeks after the comprehensive staging surgery Lab data and clinical examination: Data within 28 days before the scheduled date of surgery Neutrophil count ≧ 1,500 /mm3 Platelet count ≧ 100,000 /mm3 AST (GOT) ≦ 100 IU/L ALT (GPT) ≦ 100 IU/L Total bilirubin < 1.5 mg/dL Serum Creatinine < 1.5 mg/dL Electrocardiogram (ECG): Patients with normal ECG, Asymptomatic patients with abnormal ECGs not requiring medical intervention Neuropathy(Both motor and sensory) ≦ Grade1 (CTCAE Version 4.0) Patients expected to survive longer than 3 months from the start date of the protocol treatment Patients aged 20 years and older at the time of tentative registration (with no upper age limit) Patients who provide written informed consent for participation in this trial Exclusion Criteria: Patients assumed to have a borderline malignancy of the ovary, fallopian tube, or primary peritoneal cancer Patients who have received previous chemotherapy or radiation therapy to treat the current disease Patients who have a synchronous malignancy or who have been progression-free less than 5 years for a metachronous malignancy (Patients with basal and squamous cell carcinoma of the skin, as well as carcinoma in situ, and intramucosal carcinoma cured by local treatment, are eligible for the study) Patients with serious medical complications, such as serious heart disease, cerebrovascular accidents, uncontrolled diabetes mellitus, uncontrolled hypertension, pulmonary fibrosis, interstitial pneumonitis, active bleeding, an active gastrointestinal ulcer, or a serious neurological disorder Patients who have had a hypersensitivity reaction to polyoxyethylated or hydrogenated castor oil Patients with a pleural effusion requiring continuous drainage Patients with an active infection requiring antibiotics Patients who are pregnant, nursing or of child-bearing potential Patients with evidence upon physical examination of brain tumor and any brain metastases Patients for whom completion of this study and/or follow-up is deemed inappropriate for any reason Patients with any signs/symptoms of interstitial pneumonia
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Keiichi Fujiwara, MD, PhD
Organizational Affiliation
Saitama Medical University International Medical Center Comprehensive Cancer Center
Official's Role
Study Chair
Facility Information:
Facility Name
University of Pittsburgh
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
Pa 15213
Country
United States
Facility Name
Queen Mary Hospital
City
Hong Kong
State/Province
High West
ZIP/Postal Code
102
Country
Hong Kong
Facility Name
Aichi Cancer Center Hospital
City
Chikusa
State/Province
Aichi
ZIP/Postal Code
464-0021
Country
Japan
Facility Name
Hirosaki University School of Medicine & Hospital
City
Hirosaki-shi
State/Province
Aomori
ZIP/Postal Code
036-8203
Country
Japan
Facility Name
The Jikei University School of Medicine, Kashiwa Hospital
City
Kashiwa
State/Province
Chiba
ZIP/Postal Code
277-8567
Country
Japan
Facility Name
NHO Shikoku Cancer Center
City
Matsuyama
State/Province
Ehime
ZIP/Postal Code
791-0245
Country
Japan
Facility Name
Ehime University Hospital
City
Toon-shi
State/Province
Ehime
ZIP/Postal Code
791-0204
Country
Japan
Facility Name
University of Fukui Hospital
City
Yoshida
State/Province
Fukui
ZIP/Postal Code
910-1104
Country
Japan
Facility Name
Gunma University Hospital
City
Maebashi
State/Province
Gunma
ZIP/Postal Code
371-8511
Country
Japan
Facility Name
Gunma Prefectural Cancer Center
City
Ōta
State/Province
Gunma
ZIP/Postal Code
373-8550
Country
Japan
Facility Name
NHO Kure Medical Center And Chugoku Cancer Center
City
Kure
State/Province
Hiroshima
ZIP/Postal Code
737-0023
Country
Japan
Facility Name
Miyoshi Central Hospital
City
Miyoshi
State/Province
Hiroshima
ZIP/Postal Code
728-8502
Country
Japan
Facility Name
Hyogo Cancer Center
City
Akashi
State/Province
Hyogo
ZIP/Postal Code
673-0021
Country
Japan
Facility Name
Japanese Red Cross Society Himeji Hospital
City
Himeji
State/Province
Hyogo
ZIP/Postal Code
670-0063
Country
Japan
Facility Name
Kobe City Medical Center General Hospital
City
Kobe
State/Province
Hyogo
ZIP/Postal Code
650-0047
Country
Japan
Facility Name
Hyogo Medical College Hospital
City
Nishinomiya
State/Province
Hyogo
ZIP/Postal Code
663-8501
Country
Japan
Facility Name
Tsukuba University Hospital
City
Tsukuba
State/Province
Ibaraki
ZIP/Postal Code
305-8576
Country
Japan
Facility Name
Iwate Medical University Hospital
City
Morioka
State/Province
Iwate
ZIP/Postal Code
020-8505
Country
Japan
Facility Name
Tokai University Hospital
City
Isehara
State/Province
Kanagawa
ZIP/Postal Code
259-1143
Country
Japan
Facility Name
Nippon Medical University Musasi Kosugi Hospital
City
Kawasaki-shi
State/Province
Kanagawa
ZIP/Postal Code
211-8533
Country
Japan
Facility Name
Yokohama Municipal Citizen's Hospital
City
Yokohama
State/Province
Kanagawa
ZIP/Postal Code
240-8555
Country
Japan
Facility Name
Mie University Hospital
City
Tsu
State/Province
Mie
ZIP/Postal Code
514-8507
Country
Japan
Facility Name
Mie Prefectural General Medical Center
City
Yokkaichi
State/Province
Mie
ZIP/Postal Code
510-8561
Country
Japan
Facility Name
Tohoku University Hospital
City
Sendai
State/Province
Miyagi
ZIP/Postal Code
980-0872
Country
Japan
Facility Name
Shinshu University Hospital
City
Matsumoto
State/Province
Nagano
ZIP/Postal Code
390-0802
Country
Japan
Facility Name
Nara Medical Univeｒsity Hospital
City
Kashihara
State/Province
Nara
ZIP/Postal Code
634-8522
Country
Japan
Facility Name
Okinawa Prefectural Chubu Hospital
City
Uruma
State/Province
Okinawa
ZIP/Postal Code
904-2293
Country
Japan
Facility Name
Kaizuka City Hospital
City
Kaizuka
State/Province
Osaka
ZIP/Postal Code
597-0015
Country
Japan
Facility Name
Osaka University Hospital
City
Suita
State/Province
Osaka
ZIP/Postal Code
565-0871
Country
Japan
Facility Name
Osaka Medical College Hospital
City
Takatsuki
State/Province
Osaka
ZIP/Postal Code
569-0801
Country
Japan
Facility Name
Saitama Medical University International Medical Center
City
Hidaka
State/Province
Saitama
ZIP/Postal Code
350-1298
Country
Japan
Facility Name
Saitama Medical University Saitama Medical Center
City
Kawagoe
State/Province
Saitama
ZIP/Postal Code
350-8550
Country
Japan
Facility Name
Shizuoka Cancer Center
City
Nagaizumi
State/Province
Shizuoka
ZIP/Postal Code
411-8777
Country
Japan
Facility Name
Jichi Medical University Hospital
City
Shimotsuke
State/Province
Tochigi
ZIP/Postal Code
329-0498
Country
Japan
Facility Name
Tochigi Cancer Center
City
Utsunomiya
State/Province
Tochigi
ZIP/Postal Code
320-0834
Country
Japan
Facility Name
Juntendo University Hospital
City
Bunkyo
State/Province
Tokyo
ZIP/Postal Code
113-0033
Country
Japan
Facility Name
The University of Tokyo Hospital
City
Bunkyō-Ku
State/Province
Tokyo
ZIP/Postal Code
113-8655
Country
Japan
Facility Name
The Jikei University Daisan Hospital
City
Komae
State/Province
Tokyo
ZIP/Postal Code
201-8601
Country
Japan
Facility Name
The Cancer Institute Hospital Of JFCR
City
Koto-Ku
State/Province
Tokyo
ZIP/Postal Code
135-8550
Country
Japan
Facility Name
The Jikei University Hospital
City
Minato-Ku
State/Province
Tokyo
ZIP/Postal Code
105-8471
Country
Japan
Facility Name
Showa University Hospital
City
Shinagawa-Ku
State/Province
Tokyo
ZIP/Postal Code
142-8666
Country
Japan
Facility Name
Keio University Hospital
City
Shinjuku-Ku
State/Province
Tokyo
ZIP/Postal Code
160-8582
Country
Japan
Facility Name
Tokyo Women's Medical University Medical Center East
City
Shinjuku-Ku
State/Province
Tokyo
ZIP/Postal Code
162-0054
Country
Japan
Facility Name
Tottori University
City
Yonago
State/Province
Tottori
ZIP/Postal Code
683-8504
Country
Japan
Facility Name
Yamaguchi University Hospital
City
Ube
State/Province
Yamaguchi
ZIP/Postal Code
755-8505
Country
Japan
Facility Name
NHO Kyusyu Medical center
City
Fukuoka
ZIP/Postal Code
810-8563
Country
Japan
Facility Name
JA Hiroshima General Hospital
City
Hiroshima
ZIP/Postal Code
730-0051
Country
Japan
Facility Name
Kagoshima City Hospital
City
Kagoshima
ZIP/Postal Code
892-8580
Country
Japan
Facility Name
University Hospital, Kyoto Prefectural University of Medicine
City
Kyoto
ZIP/Postal Code
602-0841
Country
Japan
Facility Name
Saiseikai Nagasaki Hospital
City
Nagasaki
ZIP/Postal Code
850-0003
Country
Japan
Facility Name
Niigata Cancer Center Hospital
City
Niigata
ZIP/Postal Code
951-8133
Country
Japan
Facility Name
Niigata University Medical & Dental Hospital
City
Niigata
ZIP/Postal Code
951-8520
Country
Japan
Facility Name
Osaka Medical Center for Cancer and Cardiovascular Diseases
City
Osaka
ZIP/Postal Code
537-8511
Country
Japan
Facility Name
Tottori Municipal Hospital
City
Tottori
ZIP/Postal Code
680-0873
Country
Japan
Facility Name
Korea Cancer Center Hospital
City
Seoul
State/Province
Gongneung-Dong
ZIP/Postal Code
139-706
Country
Korea, Republic of
Facility Name
Gangnam Severance Hospital in Korea
City
Dogok
State/Province
Seoul
ZIP/Postal Code
250
Country
Korea, Republic of
Facility Name
Asan Medical Center
City
P'ungnap-tong
State/Province
Seoul
ZIP/Postal Code
138-736
Country
Korea, Republic of
Facility Name
Ewha Womans University Medical Center
City
Yangcheon
State/Province
Seoul
ZIP/Postal Code
1071
Country
Korea, Republic of
Facility Name
Shinchon Severance Hospital
City
Seoul
State/Province
Shinchon
ZIP/Postal Code
03722
Country
Korea, Republic of
Facility Name
University of Otago - Christchurch/Christchurch Women's Hospital
City
Christchurch
Country
New Zealand
Facility Name
KK Women's and Children's Hospital
City
Bukit Timah
ZIP/Postal Code
229899
Country
Singapore
Facility Name
National University Hospital of Singapore
City
Kent Ridge
ZIP/Postal Code
119074
Country
Singapore

12. IPD Sharing Statement

Citations:
PubMed Identifier
11870167
Citation
Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002 Mar 1;20(5):1248-59. doi: 10.1200/JCO.2002.20.5.1248.
Results Reference
background
PubMed Identifier
10963636
Citation
Neijt JP, Engelholm SA, Tuxen MK, Sorensen PG, Hansen M, Sessa C, de Swart CA, Hirsch FR, Lund B, van Houwelingen HC. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol. 2000 Sep;18(17):3084-92. doi: 10.1200/JCO.2000.18.17.3084.
Results Reference
background
PubMed Identifier
10793106
Citation
Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson RJ, Swenerton KD, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen JE, Zee B, Paul J, Baron B, Pecorelli S. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst. 2000 May 3;92(9):699-708. doi: 10.1093/jnci/92.9.699.
Results Reference
background
PubMed Identifier
12860964
Citation
Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R; Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003 Sep 1;21(17):3194-200. doi: 10.1200/JCO.2003.02.153. Epub 2003 Jul 14.
Results Reference
background
PubMed Identifier
19767092
Citation
Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, Tsuda H, Sugiyama T, Kodama S, Kimura E, Ochiai K, Noda K; Japanese Gynecologic Oncology Group. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009 Oct 17;374(9698):1331-8. doi: 10.1016/S0140-6736(09)61157-0. Epub 2009 Sep 18.
Results Reference
background
PubMed Identifier
8960474
Citation
Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK, DuBeshter B. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996 Dec 26;335(26):1950-5. doi: 10.1056/NEJM199612263352603.
Results Reference
background
PubMed Identifier
11181662
Citation
Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, Wadler S, Sickel J. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001 Feb 15;19(4):1001-7. doi: 10.1200/JCO.2001.19.4.1001.
Results Reference
background
PubMed Identifier
16394300
Citation
Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA; Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006 Jan 5;354(1):34-43. doi: 10.1056/NEJMoa052985.
Results Reference
background
PubMed Identifier
16095677
Citation
Miyagi Y, Fujiwara K, Kigawa J, Itamochi H, Nagao S, Aotani E, Terakawa N, Kohno I; Sankai Gynecology Study Group (SGSG). Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin--a Sankai Gynecology Study Group (SGSG) study. Gynecol Oncol. 2005 Dec;99(3):591-6. doi: 10.1016/j.ygyno.2005.06.055. Epub 2005 Aug 10.
Results Reference
background
PubMed Identifier
17291226
Citation
Fujiwara K, Armstrong D, Morgan M, Markman M. Principles and practice of intraperitoneal chemotherapy for ovarian cancer. Int J Gynecol Cancer. 2007 Jan-Feb;17(1):1-20. doi: 10.1111/j.1525-1438.2007.00809.x.
Results Reference
background
PubMed Identifier
17170036
Citation
Demets DL. Futility approaches to interim monitoring by data monitoring committees. Clin Trials. 2006;3(6):522-9. doi: 10.1177/1740774506073115.
Results Reference
background
PubMed Identifier
17362317
Citation
Huang HQ, Brady MF, Cella D, Fleming G. Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study. Int J Gynecol Cancer. 2007 Mar-Apr;17(2):387-93. doi: 10.1111/j.1525-1438.2007.00794.x.
Results Reference
background
PubMed Identifier
2681557
Citation
Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989 Nov;7(11):1748-56. doi: 10.1200/JCO.1989.7.11.1748.
Results Reference
background
Links:
URL
http://www.jgog.gr.jp/
Description
Japanese Gynecologic Oncology Group
URL
https://sv60.wadax.ne.jp/~gotic-jp/
Description
Gynecologic Oncology Trial and Investigation Consortium [Japanese only]

Learn more about this trial

Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial

We'll reach out to this number within 24 hrs